System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish 2 citations

PubMed: 38410026 DOI: 10.1039/d3nr06349f

Imidazolium-based zwitterionic liquid-modified PEG-PLGA nanoparticles as a potential intravenous drug delivery carrier.

Nanoscale 16(11):5584-5600

Authors: Gaya S Dasanayake, Christine M Hamadani, Gagandeep Singh, Sandeep Kumar Misra, Priyavrat Vashisth, Joshua S Sharp, Laxmi Adhikari, Gary A Baker, Eden E L Tanner

Affiliations

  • Department of Chemistry and Biochemistry, University of Mississippi, University, MS 38677, USA.
  • Department of BioMolecular Sciences, University of Mississippi, University, MS 38677, USA.
  • Department of Chemistry, University of Missouri, Columbia, MO, 65211, USA.

Abstract

Zwitterionic-based systems offer promise as next-generation drug delivery biomaterials capable of enhancing nanoparticle (NP) stimuli-responsiveness, biorecognition, and biocompatibility. Further, imidazole-functionalized amphiphilic zwitterions are able to readily bind to various biological macromolecules, enabling antifouling properties for enhanced drug delivery efficacy and bio-targeting. Herein, we describe structurally tuned zwitterionic imidazole-based ionic liquid (ZIL)-coated PEG-PLGA nanoparticles made with sonicated nanoprecipitation. Upon ZIL surface modification, the hydrodynamic radius increased by nearly 20 nm, and the surface charge significantly shifted closer to neutral. H NMR spectra suggests that the amount of ZIL on the nanoparticle surface is controlled by the structure of the ZIL and that the assembly occurs as a result of non-covalent interactions of ZIL-coated nanoparticle with the polymer surface. These nanoparticle-zwitterionic liquid (ZIL) constructs demonstrate selective affinity towards red blood cells in whole mouse blood and show relatively low human hemolysis at ∼5%. Additionally, we observe higher nanoparticle accumulation of ZIL-NPs compared with unmodified NP controls in human triple-negative breast cancer cells (MDA-MB-231). Furthermore, although the ZIL shows similar protein adsorption by SDS-PAGE, LC-MS/MS protein analysis data demonstrate a difference in the relative abundance and depletion of proteins in mouse and human serum. Hence, we show that ZIL-coated nanoparticles provide a new potential platform to enhance RBC-based drug delivery systems for cancer treatments.

MeSH

Triple Negative Breast Neoplasms, Pharmaceutical Preparations, Cells, Nanoparticles, Nanotechnology, Blood

Cited by